CD109 and prostate carcinoma: We identified “stem-like” cell populations (CD44+ and CD44+/CD133+) in aggressive metastatic prostate cancer subtypes, which was confirmed by the RNA-seq and subclonal overexpression of several EMT markers (VIM, HAS3, S100A6, ANXA2P2, ANXA2, ANXA3, AHNAK2, LOXL2, TGFB, TGFBR2, UCHL1, CD44, CD55, and CD109).